Codexis Stock (NASDAQ:CDXS), Trade Ideas

Codexis

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AHCO

ALPP

AULT

BBAI

BEAM

BIOR

BLUE

CARG

CDXS

CLDI

CLVT

CXAI

DNLI

DORM

EGIO

ELWS

FEAM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSII

IFBD

JANX

LGND

LUNR

MICS

NERV

NRXP

NVCR

PEGY

PRGO

PRIM

PRST

PTLO

PUBM

PYXS

SOUN

STGW

STRL

TBIO

TMDX

TREE

TWKS

VKTX

WDAY

WETG

Shares of  Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Equities

Nestle Sponsored representing Registered Shares Series B

NSRGY

Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI). 

Codexis Clinches Deal With Nestlé Health Science, Eyes Up To $45M Milestone In EPI Treatment Breakthrough

ADBE

ADTX

ALEC

APLS

ASLE

ASYS

ATUS

BLND

CPHC

CPTN

ENPH

ESPR

FRGT

HRYU

INTS

MIND

MRNA

MYND

NOVA

NXTC

NXTP

OCUL

OPEN

PACB

PLUG

RDFN

RILY

RPHM

SVMH

TPIC

VCIG

VIEW

Shares of Amtech Systems, Inc.  (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Codexis Inc

<h3>Gainers</h3>
<ul>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) shares moved upwards by 28.6% to $2.27 during Thursday's after-market session. The company's market cap stands at $101.4 million. As per the press release, Q4 earnings came out today. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares increased by 20.6% to $0.99. The market value of their outstanding shares is at $10.2 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) stock rose 10.84% to $0.88. The market value of their outstanding shares is at $90.3 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares moved upwards by 8.68% to $18.15. The market value of their outstanding shares is at $791.7 million. The company's, Q4 earnings came out today. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) stock increased by 7.58% to $1.84. The company's market cap stands at $3.2 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares rose 6.98% to $0.76. The market value of their outstanding shares is at $20.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares decreased by 25.4% to $2.09 during Thursday's after-market session. The company's market cap stands at $199.2 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock declined by 20.52% to $3.44. The company's market cap stands at $356.4 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) stock decreased by 14.07% to $0.28. The company's market cap stands at $42.5 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares fell 10.82% to $16.5. The company's market cap stands at $67.0 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock fell 9.02% to $1.11. The company's market cap stands at $18.6 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares fell 8.61% to $4.25. The market value of their outstanding shares is at $296.7 million. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMRA

CRDF

DTIL

GRTS

HLTH

HUMA

LSDI

YMAB

12 Health Care Stocks Moving In Thursday's After-Market Session

Benchmark analyst Robert Wasserman upgrades Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) from Hold to Buy and announces $9 price target.

Upgrades

Price Target

Analyst Ratings

Benchmark Upgrades Codexis to Buy, Announces $9 Price Target

Guidance

Codexis Sees FY24 Product Revenue $38M-$42M, Excluding Revenue Related To PAXLOVID; R&D Revenue $18M-$22M

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Codexis beat estimated earnings by 17.0%, reporting an EPS of $-0.1 versus an estimate of $-0.12.
Revenue was down $3.81 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.06 which was followed by a 7.000000000000001% increase in the share price the next day.
Here's a look at Codexis's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.32</td>
<td>-0.23</td>
<td>-0.31</td>
<td>-0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.26</td>
<td>-0.17</td>
<td>-0.34</td>
<td>-0.19</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>10.03M</td>
<td>18.09M</td>
<td>14.09M</td>
<td>28.92M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>9.28M</td>
<td>21.32M</td>
<td>12.98M</td>
<td>30.38M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Codexis <a href="https://www.benzinga.com/quote/CDXS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Codexis Q4 Earnings

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. The company reported quarterly sales of $26.56 million which beat the analyst consensus estimate of $19.90 million by 33.47 percent. This is a 12.56 percent decrease over sales of $30.38 million the same period last year.

Earnings Beats

Codexis Q4 2023 GAAP EPS $(0.10) Beats $(0.12) Estimate, Sales $26.56M Beat $19.90M Estimate

Shares of Helix Energy Solutions Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlx#NYSE">HLX</a>) fell sharply during Tuesday&rsquo;s session following weak earnings.
Helix Energy posted adjusted earnings of 6 cents per share, missing market estimates of 10 cents per share. The company&rsquo;s quarterly sales came in at $335.16 million versus expectations of $315.60 million.
Helix Energy Solutions shares dipped 11% to $9.13 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares jumped 145% to $37.00 after the company announced updated clinical data for both of its clinical programs.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) surged 72% to $0.5657.</li>
<li>Viking Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vktx#NASDAQ">VKTX</a>) shares jumped 71.2% to $65.88 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) gained 67% to $2.58.</li>
<li>WeTrade Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wetg#NASDAQ">WETG</a>) gained 50% to $3.36.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>) climbed 33.6% to $13.70 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Biora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bior#NASDAQ">BIOR</a>) surged 32.2% to $1.39.</li>
<li>AdaptHealth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahco#NASDAQ">AHCO</a>) jumped 29.6% to $9.89 following fourth-quarter results.</li>
<li>Codexis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdxs#NASDAQ">CDXS</a>) rose 29% to $4.1283. Codexis entered into exclusive licensing agreement with Roche for double-stranded DNA Ligase.</li>
<li>Beam Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beam#NASDAQ">BEAM</a>) gained 26.8% to $45.43 after the company reported fourth-quarter financial results.</li>
<li>BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) rose 26% to $3.14. Cantor Fitzgerald analyst Yi Fu Lee maintained BigBear.ai with an Overweight and maintained $3 price target.</li>
<li>5E Advanced Materials, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/feam#NASDAQ">FEAM</a>) gained 24.3% to $1.84.</li>
<li>Earlyworks Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elws#NASDAQ">ELWS</a>) gained 24.2% to $0.7321. Earlyworks was selected as a co-creation partner for MetaMe&reg; a meta-communication service utilizing cutting-edge technology from NTT DOCOMO, one of Japan&#39;s largest cell phone operators.</li>
<li>The Singing Machine Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mics#NASDAQ">MICS</a>) rose 24.1% to $0.9012.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) jumped 24% to $0.3299.</li>
<li>Ligand Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgnd#NASDAQ">LGND</a>) gained 23% to $91.68 following upbeat quarterly earnings.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) jumped 22.3% to $7.03 after gaining more than 46% on Monday.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) gained 21.3% to $5.80. Pyxis Oncology announced a $50 million private placement.</li>
<li>PubMatic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pubm#NASDAQ">PUBM</a>) shares climbed 20.8% to $20.01 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) jumped 20.5% to $1.76.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) gained 20.4% to $13.63.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) jumped 19% to $107.00 after the company reported fourth-quarter financial results.</li>
<li>Denali Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dnli#NASDAQ">DNLI</a>) gained 17.6% to $19.87 following quarterly results.</li>
<li>National Vision Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eye#NASDAQ">EYE</a>) rose 17.6% to $23.48 following strong results.</li>
<li>Heidrick &amp; Struggles International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsii#NASDAQ">HSII</a>) gained 16.7% to $33.81 following strong results.</li>
<li>Ault Alliance, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ault#NASDAQ">AULT</a>) rose 15.8% to $0.4520. Ault Alliance announced record preliminary 2023 revenue of $153 million.</li>
<li>Portillo&#39;s Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptlo#NASDAQ">PTLO</a>) gained 15.6% to $15.90 following upbeat results.</li>
<li>Dorman Products, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dorm#NASDAQ">DORM</a>) climbed 11.5% to $92.67 following upbeat earnings.</li>
<li>Constellation Energy Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ceg#NASDAQ">CEG</a>) gained 9.7% to $146.27 following strong sales..</li>
<li>NovoCure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvcr#NASDAQ">NVCR</a>) gained 9.5% to $16.31.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) gained 9.5% to $85.14 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Minerva Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nerv#NASDAQ">NERV</a>) shares dipped 56.9% to $2.93 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) fell 55.8% to $1.2180. The stock continues to experience marked volatility after the company on Monday said it encountered an unexpected delay in its planned reverse stock split.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrxp#NASDAQ">NRXP</a>) fell 32.7% to $0.2878 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.</li>
<li>Thoughtworks Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/twks#NASDAQ">TWKS</a>) fell 30.6% to $3.20 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.</li>
<li>Alpine 4 Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpp#NASDAQ">ALPP</a>) dipped 26% to $0.8799.</li>
<li>Stagwell Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stgw#NASDAQ">STGW</a>) fell 25.6% to $5.22 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) dipped 24.9% to $0.9084.</li>
<li>Clarivate Plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clvt#NYSE">CLVT</a>) fell 23.3% to $6.85 after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Edgio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egio#NASDAQ">EGIO</a>) fell 21.5% to $0.2450. Edgio announced effectiveness of reverse stock split.</li>
<li>Telesis Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbio#NASDAQ">TBIO</a>) fell 21% to $0.5215 after tumbling 15% on Monday. Telesis Bio said it sees preliminary 2023 total consolidated revenue of $27.5 million.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) dipped 20.3% to $11.36.</li>
<li>Pineapple Energy Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pegy#NASDAQ">PEGY</a>) shares fell 19.6% to $0.0654. On Feb. 5. Pineapple Energy priced a $1 million registered direct offering of common stock.</li>
<li>The Aaron&#39;s Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aan#NYSE">AAN</a>) shares fell 16.7% to $8.71. Aaron&#39;s reported a loss for the fourth quarter, while sales missed estimates.</li>
<li>Perrigo Company plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prgo#NYSE">PRGO</a>) fell 15.1% to $27.33 after the company reported fourth quarter financial results.</li>
<li>Intuitive Machines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lunr#NASDAQ">LUNR</a>) fell 10% to $5.64. Intuitive Machines said communications with moon lander Odysseus is expected to cease Tuesday morning, effectively ending mission 5 days after touchdown, Reuters reported.</li>
<li>Unity Software Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/u#NYSE">U</a>) fell 8.3% to $30.31 after the company reported mixed financial results for its fourth quarter. The company said it sees first-quarter strategic portfolio revenue in the range of $415 million to $420 million.</li>
<li>Primoris Services Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prim#NASDAQ">PRIM</a>) dipped 7.2% to $ 37.63 after the company reported mixed fourth quarter financial results.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) fell 6.9% to $31.90 following weak sales.</li>
<li>CarGurus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/carg#NASDAQ">CARG</a>) shares fell 4.2% to $22.89 after the company reported fourth-quarter financial results.</li>
<li>Workday, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wday#NASDAQ">WDAY</a>) shares declined 2.9% to $298.42 after the company reported fourth-quarter financial results, reiterated guidance and announced its intent to acquire HiredScore.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37328014/how-to-earn-500-a-month-from-ebay-stock-ahead-of-q4-earnings-report"> How To Earn $500 A Month From eBay Stock Ahead Of Q4 Earnings Report </a>

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. </li>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares moved upwards by 91.96% to $73.87. The company's market cap stands at $7.4 billion. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares moved upwards by 41.81% to $2.34. The company's market cap stands at $156.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares rose 33.24% to $1.4. The market value of their outstanding shares is at $38.0 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares increased by 31.4% to $4.21. The company's market cap stands at $293.6 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares moved upwards by 31.02% to $13.43. The company's market cap stands at $2.8 billion. As per the news, the Q4 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock decreased by 57.1% to $2.92 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock declined by 32.77% to $0.29. The company's market cap stands at $24.4 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares decreased by 24.93% to $0.91. The market value of their outstanding shares is at $32.2 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock fell 21.22% to $0.52. The company's market cap stands at $15.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares decreased by 15.21% to $0.49. The company's market cap stands at $2.5 million. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) stock decreased by 14.15% to $17.64. The market value of their outstanding shares is at $714.2 million. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTMX

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SIBN

12 Health Care Stocks Moving In Tuesday's Intraday Session

WIIM

Codexis shares are trading higher after the company announced that it entered into an exclusive licensing agreement for newly engineered double-stranded DNA ligase with Roche.

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) stock rose 120.5% to $33.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares increased by 97.24% to $75.9. The market value of their outstanding shares is at $7.6 billion. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock rose 22.2% to $95.0. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares rose 21.24% to $3.88. The market value of their outstanding shares is at $270.9 million. </li>
<li>Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) shares moved upwards by 20.93% to $90.0. The company's market cap stands at $1.5 billion. The company's, Q4 earnings came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares rose 19.5% to $12.25. The company's market cap stands at $2.5 billion. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares decreased by 22.9% to $0.33 during Tuesday's pre-market session. The company's market cap stands at $28.0 million. </li>
<li>Veradigm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>) shares decreased by 22.03% to $6.48. The market value of their outstanding shares is at $708.0 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares decreased by 18.32% to $13.07. The market value of their outstanding shares is at $53.1 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares fell 14.79% to $1.21. The market value of their outstanding shares is at $31.8 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares fell 11.54% to $1.15. The company's market cap stands at $56.4 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock fell 10.23% to $0.43. The market value of their outstanding shares is at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BEAT

BSGM

MDRX

MNOV

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Biotech

General

RHHBF

Codexis Enters Exclusive Licensing Agreement With Roche For Double-Stranded DNA Ligase

Term loan agreement enables Company to accelerate development and enhance commercialization of&nbsp;ECO Synthesis&#x2122; manufacturing platform for RNAi therapeutics
Financing bolsters cash position and provides additional flexibility on projected runway through&nbsp;positive cash-flow around end of 2026
Codexis management to host conference call today at 4:30 pm ET
REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has entered into a loan facility agreement with an affiliate of Innovatus Capital Partners, LLC (Innovatus) for up to $40 million, including $30 million upfront and access to an additional $10 million upon achieving certain prespecified revenue thresholds. This loan facility reinforces the strength of Codexis' cash position, provides additional flexibility to its projected runway through cash-flow positive around the end of 2026 and will support the ongoing development and commercialization of the Company's Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform.
"The rapid technical progress we have made with our ECO Synthesis&#x2122; manufacturing platform has exceeded our expectations and opened the door for us to make targeted investments in accelerating our technology's value creation. After a competitive process, we are excited to partner with a leading financier like Innovatus, who truly understand the incredible opportunity that RNAi therapeutics represents," said Stephen Dilly, MBBS, PhD, Chief Executive Officer of Codexis. "By opening this line of non-dilutive capital, we can prudently deploy a portion of the funds to support our ambitions of growing up the value chain by building out a small-scale facility for making siRNA at the lab level—our planned ECO Synthesis&#x2122; Innovation Lab. This financing, combined with the anticipated return to growth of our Pharmaceutical Manufacturing business this year, gives Codexis the time and financial cushion to realize the full potential of our ECO Synthesis&#x2122; manufacturing platform."
The planned ECO Synthesis&#x2122; Innovation Lab will support both technical advancement and commercialization efforts related to the Company's ECO Synthesis&#x2122; manufacturing platform. Notably, in addition to providing a strong basis for partnering discussions and early access customer testing, this facility will enable the Company to develop new RNAi constructs, test new nucleotide modifications and conjugation modalities, develop tech transfer protocols and ensure flexibility with a small-scale footprint before potentially embarking on a full-scale GMP facility.
"Upon examining the forecasted demand for RNAi therapeutics, we see strong potential upside to supporting the development of Codexis' ECO Synthesis&#x2122; manufacturing platform," said Claes Ekstrom, Managing Director and Head of Life Sciences at Innovatus. "Between the Company's innovative technology, foundational revenue-generating business, and highly experienced leadership team, we're confident in the growth potential of Codexis and are excited to be a part of their story moving forward."
Following the closing of the term loan agreement, Codexis retained approximately $29 million in net proceeds from the first tranche. The loan carries an interest-only period of 36 months and a total term of 60 months. Additional details regarding the financing will be included in a Current Report on Form 8-K, which Codexis expects to file with the Securities and Exchange Commission within four business days of the date of this press release.
Armentum Partners acted as the Company's exclusive financial advisor on this transaction.

Financing

Contracts

Codexis Secures $40M In Strategic Financing Deal With Innovatus Capital Partners To Further Strengthen Cash Position Ahead Of Key Milestones

<h3>Gainers</h3>
<ul>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) shares increased by 9.3% to $0.15 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares rose 8.58% to $0.54. The company's market cap stands at $2.4 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares moved upwards by 6.98% to $2.45. The market value of their outstanding shares is at $7.5 million. </li>
<li>Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) shares moved upwards by 6.62% to $0.92. The market value of their outstanding shares is at $160.9 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares rose 6.01% to $2.29. The market value of their outstanding shares is at $10.7 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares rose 5.81% to $2.91. The market value of their outstanding shares is at $203.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kiora Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) stock declined by 10.6% to $0.76 during Thursday's after-market session. The company's market cap stands at $5.8 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares fell 7.74% to $3.1. The market value of their outstanding shares is at $4.4 million. </li>
<li>Adagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) shares fell 7.5% to $3.33. The company's market cap stands at $145.9 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares declined by 7.1% to $0.38. The market value of their outstanding shares is at $5.8 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares fell 7.03% to $0.81. The company's market cap stands at $5.3 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares fell 6.48% to $0.56. The market value of their outstanding shares is at $16.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAG

ALZN

BRTX

CING

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

LCTX

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

OGEN

PXMD

RDHL

STSS

Codexis, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdxs#NASDAQ">CDXS</a>) entered a purchase deal with&nbsp;Nestl&eacute; S.A.(OTC: <a class="ticker" href="https://www.benzinga.com/stock/nsrgy#OTC">NSRGY</a>) Nestl&eacute; Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI).&nbsp;
Under the terms of the agreement, Codexis will receive up to $45 million in potential milestone payments, including a $5 million upfront payment, as well as single-digit net-sales-based royalties.
Codexis will receive up to an additional $5 million if Nestl&eacute; Health Science exercises an option to purchase two additional early-stage enzymes being developed for EPI.
CDX-7108 is a lipase variant specifically engineered to overcome the limitations of traditional pancreatic enzyme replacement therapy (PERT) deficiencies. PERT is the main treatment for EPI, a debilitating condition of the gastrointestinal tract that is caused by conditions that impair pancreatic function.
Stephen Dilly, CEO of Codexis, said, &quot;Preliminary data from the CDX-7108 Phase I study announced earlier this year support continued investigation into Phase II clinical studies. We believe that CDX-7108 could represent a meaningful advance in the standard of care for patients, and we are pleased to retain an economic interest in the program as Nestl&eacute; continues development.&quot;
Nestl&eacute; Health Science will be exclusively responsible for further advancing and marketing CDX-7108, covering all related expenses.
Price Action: CDXS shares are trading higher by 4.52% at $3.47&nbsp;on the last check Wednesday.&nbsp;
Disclaimer: This content was partially produced with the help of AI tools and was Reviewed And Published By Benzinga Editors.

Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency (EPI). Under the terms of the agreement, Codexis will receive up to $45M in potential milestone payments, including a $5M upfront payment, as well as single-digit net-sales-based royalties. Codexis will receive up to an additional $5M if Nestlé Health Science exercises an option to purchase two additional early-stage enzymes being developed for EPI. Nestlé Health Science will be solely responsible for the continued development and commercialization of CDX-7108, including all associated costs. &nbsp;
"This agreement solidifies the future development of CDX-7108—a potential new therapy that could be added to the treatment armamentarium for patients with exocrine pancreatic insufficiency—and enables Codexis to focus resources on the advancement of our ECO Synthesis&#x2122; platform and the return to growth of our Pharmaceutical Manufacturing business," said Stephen Dilly, MBBS, PhD, Chief Executive Officer of Codexis. "Preliminary data from the CDX-7108 Phase I study announced earlier this year support continued investigation into Phase II clinical studies. We believe that CDX-7108 could represent a meaningful advance in the standard of care for patients, and we are pleased to retain an economic interest in the program as Nestlé continues development."
Codexis and Nestlé Health Science completed pre-clinical work for CDX-7108 and a Phase I clinical trial under the terms of a previous agreement. With this asset purchase agreement, Nestlé Health Science may continue advancing the compound through the development process.
About CDX-7108 CDX-7108 is a lipase variant specifically engineered to overcome the limitations of traditional pancreatic enzyme replacement therapy (PERT) deficiencies. PERT is the main treatment for exocrine pancreatic insufficiency (EPI), a debilitating condition of the gastrointestinal tract that is caused by conditions that impair pancreatic function, such as pancreatitis, pancreatic cancer, Cronh's disease, celiac disease and cystic fibrosis. CDX-7108 was engineered to be highly stable to the acidic conditions of the stomach and resistant to proteases in the upper intestines. Preliminary data from an interim analysis of the Phase I study proof-of-concept arm supported continued investigation into Phase II clinical studies.

Codexis Announces Purchase Agreement With Nestlé Health Science For CDX-7108;  Under The Terms, Codexis Will Receive Up To $45M In Potential Milestone Payments, Including A $5M Upfront Payment, As Well As Single-Digit Net-Sales-Based Royalties

Shares of Amtech Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asys#NASDAQ">ASYS</a>) shares fell sharply during Thursday&rsquo;s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.
Amtech reported quarterly sales of $27.70 million, missing the analyst consensus estimate of $34.50 million. The company anticipated first-quarter revenue to be between $21 million and $24 million, versus the $34.15 million estimate.
Benchmark analyst Mark Miller downgraded Amtech Systems from Buy to Hold.
Amtech Systems shares fell 30.6% to $4.16 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Freight Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frgt#NASDAQ">FRGT</a>) shares jumped 322% to $1.14 after the company announced Amazon Mexico renewed its selection of Fr8App for its logistical solutions.</li>
<li>SRIVARU Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/svmh#NASDAQ">SVMH</a>) rose 74.8% to $0.7000.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xbp#NASDAQ">XBP</a>) shares gained 49% to $8.46 after declining around 20% on Wednesday.</li>
<li>TPI Composites, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tpic#NASDAQ">TPIC</a>) rose 46% to $3.1350 as the company announced refinancing transaction with Oaktree, significantly strengthening company&rsquo;s liquidity position and enhancing financial flexibility.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) rose 43.6% to $0.0280 after the company signed a letter of intent outlining investment in Lynx Motors.</li>
<li>Canterbury Park Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cphc#NASDAQ">CPHC</a>) rose 31% to $18.70.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) gained 29% to $5.14.</li>
<li>Hanryu Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hryu#NASDAQ">HRYU</a>) gained 27.1% to $1.3850 after jumping 28% on Wednesday.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) shares climbed 23.2% to $1.8603. Esperion said that the FDA updated LDL-C lowering indication for NEXLETOL (bempedoic acid) tablet and NEXLIZET (bempedoic acid and ezetimibe) tablet.</li>
<li>Redfin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdfn#NASDAQ">RDFN</a>) gained 21.8% to $10.26.</li>
<li>Codexis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdxs#NASDAQ">CDXS</a>) shares surged 20.5% to $2.5184. Codexis announced achievement of gram-scale synthesis with its ECO Synthesis platform.</li>
<li>Vista Gold Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vgz#NYSE">VGZ</a>) gained 20% to $0.4010. Vista Gold announced a $20 million royalty with Wheaton Precious Metals Corp. on Mt Todd.</li>
<li>Altice USA, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atus#NYSE">ATUS</a>) rose 18.8% to $2.4950.</li>
<li>Sunnova Energy International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nova#NYSE">NOVA</a>) gained 18.3% to $14.09.</li>
<li>Wayfair Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/w#NYSE">W</a>) rose 17.3% to $66.75.</li>
<li>Sunrun Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/run#NASDAQ">RUN</a>) gained 16.7% to $17.42.</li>
<li>Blend Labs, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/blnd#NYSE">BLND</a>) surged 16.7% to $2.1950. Blend Labs Head of Finance and Admin. Amir Jafari acquired a total of 12,610 shares at an average price of $1.22.</li>
<li>Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) rose 15.8% to $91.14. Moderna and Merck &amp; Co announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection.</li>
<li>VCI Global Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcig#NASDAQ">VCIG</a>) gained 15.4% to $2.62 after its financial technology arm, Accuventures Sdn Bhd, agreed to acquire the Malaysian digital platform EVOLET.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacb#NASDAQ">PACB</a>) surged 14.2% to $10.12. Stephens &amp; Co. initiated coverage on Pacific Biosciences with an Overweight rating and announced a price target of $11.</li>
<li>Alector, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alec#NASDAQ">ALEC</a>) rose 14.8% to $7.92. Stifel upgraded Alector from Hold to Buy and raised the price target from $8 to $15.</li>
<li>Opendoor Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/open#NASDAQ">OPEN</a>) gained 14.4% to $4.71.</li>
<li>Enphase Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/enph#NASDAQ">ENPH</a>) rose 13.6% to $122.22.</li>
<li>Plug Power Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plug#NASDAQ">PLUG</a>) gained 12.7% to $4.8550.</li>
<li>Alcoa Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aa#NYSE">AA</a>) gained 11% to $28.84. Alcoa received approval for continued mining in Western Australia.</li>
<li>RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) gained 7.3% to $304.60.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reneo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rphm#NASDAQ">RPHM</a>) shares dipped 87.3% to $0.9861. Reneo Pharmaceuticals said its pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or secondary efficacy endpoint.</li>
<li>Mynd.ai, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mynd#NYSE">MYND</a>) fell 53.1% to $2.71.</li>
<li>Cepton, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cptn#NASDAQ">CPTN</a>) fell 24.2% to $3.01 after the company posted downbeat third-quarter sales and issued weak FY23 revenue forecast. Craig-Hallum downgraded Cepton from Buy to Hold.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apls#NASDAQ">APLS</a>) declined 20.7% to $49.81 after the company announced it was informed of a negative trend vote on the marketing authorization application for pegcetacoplan.</li>
<li>NextCure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtc#NASDAQ">NXTC</a>) fell 20.7% to $1.15 after the company issued year-end clinical pipeline updates.</li>
<li>MIND Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mind#NASDAQ">MIND</a>) dipped 19.4% to $4.7414 following weak quarterly results.</li>
<li>Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) fell 16.4% to $5.26.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) shares fell 15.1% to $3.3450. Ocular Therapeutix priced its public offering of 30.8 million common share stock at $3.25 per share for gross proceeds of $100.1 million.</li>
<li>NextPlay Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtp#NASDAQ">NXTP</a>) shares fell 11.4% to $1.3905 after jumping 68% on Wednesday.</li>
<li>Regis Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rgs#NYSE">RGS</a>) shares fell 9.9% to $8.39. NYSE will begin delisting proceedings against Regis Corp.</li>
<li>ABM Industries Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>) dipped 9.5% to $47.33. ABM recently reported better-than-expected fourth-quarter financial results and issued guidance.</li>
<li>Intensity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ints#NASDAQ">INTS</a>) shares fell 9.4% to $8.94 after jumping 22% on Wednesday. Intensity Therapeutics recently named Joseph Talamo as CFO.</li>
<li>AerSale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asle#NASDAQ">ASLE</a>) shares fell 8% to $13.60. AerSale priced its secondary offering of 4 million common shares.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) fell 7.6% to $19.95.</li>
<li>Adobe Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adbe#NASDAQ">ADBE</a>) fell 6.2% to $585.55. Adobe posted upbeat earnings for its fourth quarter, but issued weak sales forecast for full-year 2024.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36231379/wait-for-a-pullback-youre-late-to-the-party-jim-cramer-says-about-this-tech-stock"> &#39;Wait For A Pullback &mdash; You&#39;re Late To The Party&#39;: Jim Cramer Says About This Tech Stock</a>

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) stock moved upwards by 38.3% to $8.23 during Thursday's regular session. The market value of their outstanding shares is at $216.5 million. </li>
<li>Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) shares rose 36.11% to $5.68. The company's market cap stands at $112.7 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) stock moved upwards by 32.1% to $2.76. The company's market cap stands at $192.8 million. </li>
<li>Science 37 Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCE#NASDAQ">SNCE</a>) stock moved upwards by 26.69% to $5.18. The company's market cap stands at $30.9 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) shares rose 25.9% to $6.12. The market value of their outstanding shares is at $259.9 million. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) stock increased by 25.62% to $1.0. The company's market cap stands at $10.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reneo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) stock declined by 81.9% to $1.4 during Thursday's regular session. The market value of their outstanding shares is at $46.6 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares declined by 22.85% to $0.62. The company's market cap stands at $1.9 million. </li>
<li>Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) shares fell 22.25% to $48.9. The company's market cap stands at $5.7 billion. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock declined by 21.73% to $1.14. The market value of their outstanding shares is at $31.6 million. </li>
<li>Motus GI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOTS#NASDAQ">MOTS</a>) shares decreased by 19.66% to $2.78. The market value of their outstanding shares is at $1.9 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 16.91% to $8.21. The company's market cap stands at $112.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IMMX

MOTS

RNXT

SNCE

STTK

THMO

TLSI

12 Health Care Stocks Moving In Thursday's Intraday Session

Shares of Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors.
Nxu, shares rose 42.1% to $0.0278 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>XBP Europe Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xbp#NASDAQ">XBP</a>) shares rose 150% to $14.20 in pre-market trading after declining around 20% on Wednesday.</li>
<li>Hanryu Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hryu#NASDAQ">HRYU</a>) gained 34.8% to $1.47 in pre-market trading after jumping 28% on Wednesday.</li>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares gained 21.1% to $0.0850 in pre-market trading.</li>
<li>Codexis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdxs#NASDAQ">CDXS</a>) shares surged 20.5% to $2.52 in pre-market trading. Codexis announced achievement of gram-scale synthesis with its ECO Synthesis platform.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) shares climbed 15.2% to $1.74 in pre-market trading. Esperion said that the FDA updated LDL-C lowering indication for NEXLETOL (bempedoic acid) tablet and NEXLIZET (bempedoic acid and ezetimibe) tablet.</li>
<li>Blue Water Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bwv#NASDAQ">BWV</a>) shares rose 14.9% to $0.3109 in pre-market trading after gaining 7% on Wednesday.</li>
<li>Ekso Bionics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ekso#NASDAQ">EKSO</a>) gained 14.6% to $1.33 in pre-market trading after falling 15% on Wednesday.</li>
<li>Nubia Brand International Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nubi#NASDAQ">NUBI</a>) rose 13.8% to $11.00 in pre-market trading after falling 9% on Wednesday.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snoa#NASDAQ">SNOA</a>) shares gained 11.1% to $0.19 in pre-market trading.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Amtech Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asys#NASDAQ">ASYS</a>) shares fell 26.4% to $4.41 in pre-market trading after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.</li>
<li>Regis Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rgs#NYSE">RGS</a>) shares fell 22.6% to $7.20 in pre-market trading. NYSE will begin delisting proceedings against Regis Corp.</li>
<li>Cepton, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cptn#NASDAQ">CPTN</a>) fell 22.4% to $3.08 in pre-market trading after the company posted downbeat third-quarter sales and issued weak FY23 revenue forecast.</li>
<li>NextPlay Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtp#NASDAQ">NXTP</a>) shares fell 18.4% to $1.28 in pre-market trading after jumping 68% on Wednesday.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) shares fell 18% to $3.23 in pre-market trading. Ocular Therapeutix priced its public offering of 30.8 million common share stock at $3.25 per share for gross proceeds of $100.1 million.</li>
<li>Applied UV, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auvi#NASDAQ">AUVI</a>) shares fell 14.5% to $1.59 in pre-market trading after declining around 10% on Wednesday. Applied UV teamed with Silver Cross Hospital in New Lenox, Illinois for the implementation of the groundbreaking Far-UVC Puro Protect 222nm fixtures in the hospital&#39;s Sterile Processing Department (SPD).</li>
<li>Shattuck Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sttk#NASDAQ">STTK</a>) fell 13.5% to $4.20 in pre-market after gaining 130% on Wednesday. Shattuck Labs announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in frontline high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML) patients.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phio#NASDAQ">PHIO</a>) fell 11.8% to $0.6873 in pre-market trading after declining 9% on Wednesday. Phio Pharmaceuticals recently announced it will exercise warrants for $2.8 million in gross proceeds.</li>
<li>Intensity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ints#NASDAQ">INTS</a>) shares fell 8.4% to $9.05 in pre-market trading after jumping 22% on Wednesday. Intensity Therapeutics recently named Joseph Talamo as CFO.</li>
<li>Adobe Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adbe#NASDAQ">ADBE</a>) fell 6.1% to $586.38 in pre-market trading. Adobe posted upbeat earnings for its fourth quarter, but issued weak sales forecast for full-year 2024.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/12/36231450/lennar-gears-up-for-q4-print-heres-a-look-at-recent-price-target-changes-by-the-most-accurate-analy"> Lennar Gears Up For Q4 Print; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>

Pre-Market Outlook

AUVI

EKSO

NUBI

PHIO

SNOA

Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock increased by 22.3% to $0.47 during Thursday's pre-market session. The market value of their outstanding shares is at $6.1 million. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares rose 21.85% to $1.84. The company's market cap stands at $209.2 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock increased by 20.98% to $0.92. The company's market cap stands at $19.8 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 20.34% to $0.59. The market value of their outstanding shares is at $7.2 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) stock moved upwards by 19.61% to $2.5. The company's market cap stands at $174.5 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) stock rose 19.28% to $0.68. The market value of their outstanding shares is at $15.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) shares fell 19.3% to $1.17 during Thursday's pre-market session. The market value of their outstanding shares is at $32.6 million. </li>
<li>Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) shares declined by 14.13% to $54.0. The company's market cap stands at $6.3 billion. </li>
<li>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) stock fell 13.96% to $3.39. The market value of their outstanding shares is at $269.2 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 13.7% to $0.39. The market value of their outstanding shares is at $8.2 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) stock declined by 10.43% to $4.47. The company's market cap stands at $223.8 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares declined by 10.0% to $0.37. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

FEMY

GLUE

IONM

KTTA

RSLS

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 25.6% to $1.08 during Wednesday's after-market session. The market value of their outstanding shares is at $34.8 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 10.14% to $3.04. The market value of their outstanding shares is at $2.1 million. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares increased by 10.04% to $2.3. The market value of their outstanding shares is at $160.6 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 8.5% to $0.37. The market value of their outstanding shares is at $19.5 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) shares rose 8.47% to $0.06. The market value of their outstanding shares is at $12.3 million. </li>
<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) shares increased by 6.49% to $0.15. The market value of their outstanding shares is at $14.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares decreased by 16.2% to $4.18 during Wednesday's after-market session. The market value of their outstanding shares is at $209.3 million. </li>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) stock fell 15.43% to $8.06. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) shares fell 14.22% to $3.38. The company's market cap stands at $268.4 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock decreased by 13.84% to $0.35. The company's market cap stands at $2.3 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares fell 10.01% to $0.05. The market value of their outstanding shares is at $12.3 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares fell 7.57% to $1.1. The market value of their outstanding shares is at $31.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVTX

BDRX

CADL

Morgan Stanley Capital Protected Notes for S&P 500 Index

NCNA

ONMD

PIRS

TCRT

12 Health Care Stocks Moving In Wednesday's After-Market Session

Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics &nbsp;
Company remains on track to initiate pre-commercial customer testing in 2024
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; technology. This critical technical milestone demonstrates the preparative-scale manufacture of an oligonucleotide, composed of the modified nucleotide building blocks typically used in ribonucleic acid (RNA) therapeutics, under process-like conditions.
Successful completion of this milestone enables Codexis engineers to initiate a comprehensive assessment of the purity profile for small interference RNA (siRNA) developed with ECO Synthesis&#x2122; technology. Separately, data collected on process-related parameters provides foundational information for early models of the siRNA manufacturing process and allows the Company to open conversations with early access customers on their RNA interference (RNAi) therapeutics manufacturing processes. Early access customer testing is on track to initiate in 2024 ahead of an anticipated full commercial launch in 2026.
"Our scientists have done outstanding work to bring us to this critical milestone for the development of our ECO Synthesis&#x2122; technology so rapidly. We have increased production scale by four orders of magnitude since August to move into preparative scale of the oligonucleotide. This is significant because it allows our engineers to begin modeling and testing manufacturing methods with confidence, which will enable us to start sharing data-driven insights with potential customers on key metrics like purity profile," said Stephen Dilly, MBBS, PhD, Chief Executive Officer of Codexis. "Furthermore, we have demonstrated the ability of our enzymes to include modified building blocks reliably and with high conversion efficiency in a timely fashion. This, together with our steady progress in the enzymatic synthesis of the nucleotide building blocks and starter oligonucleotide, gives us real excitement for the potential of the ECO Synthesis&#x2122; platform and we look forward to initiating pre-commercial testing next year."
The need for an enzymatic route of synthesis for RNAi therapeutics was recently reinforced at the Company's virtual KOL investor event featuring John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuticals and Codexis Strategic Advisory Board member, and David Butler, PhD, Chief Technology Officer of Hongene Biotech Company. These distinguished experts were joined by Codexis leadership and discussed the growth of RNAi therapeutics as a modality, the manufacturing landscape and the potential role for Codexis' ECO Synthesis&#x2122; platform to enable commercial-scale production of RNAi therapeutics. A replay of the virtual event is accessible on the Investor Relations section of the Company's website, <a href="https://www.globenewswire.com/Tracker?data=oUxW4noSiAY_AxueKn_2DnOlE_zVlRaLfN32zWQOYFvw1YtleI2vTDKOfJD2WYnwpf4aBmi2llgttnRo81lcjEW2mx6F5kWJwew5jeBZ0xc=">https://ir.codexis.com</a>.

Codexis Announces Achievement Of Gram-Scale Synthesis With Its ECO Synthesis Platform; Milestone Enables Codexis Engineers To Model The Manufacturing Process For RNai Therapeutics

Codexis GAAP EPS of -$0.10 beats by $0.04, revenue of $26.56M beats by $7.63M